Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 11, No 1 (2015) PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
A. V. Rudakova
"... that apixaban was projected to increase life expectancy of the patients with NVAF compared with standards ..."
 
Vol 10, No 3 (2014) COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION Abstract  similar documents
A. V. Rudakova, V. A. Parfenov
"... in patients with NVAF in the Russian Federation. Aim. To evaluate the cost-effectiveness ratio of apixaban ..."
 
Vol 13, No 1 (2017) CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
S. V. Nedogoda, I. N. Barykina, A. S. Salasiuk, V. O. Smirnova
"... and apixaban in patients with non-valvular atrial fibrillation (AF) and to assess the impact of the both ..."
 
Vol 11, No 3 (2015) ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
A. V. Rudakova
"... administration of vitamin K antagonists (warfarin) or the new oral anticoagulants (apixaban, dabigatran ..."
 
Vol 11, No 6 (2015) Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events Abstract  similar documents
O. V. Shatalova
"... Aim. Pharmacoeconomic analysis of apixaban use compared to conventional therapy in patients ..."
 
Vol 9, No 3 (2013) ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT Abstract  similar documents
E. L. Dolgova, I. M. Sokolov, Yu. G. Shvarts
"... неклапанной фибрилляции предсердий, об особенностях антикоагулянтной терапии при данной патологии и трудностях ..."
 
Vol 13, No 6 (2017) PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS Abstract  similar documents
A. А. Sokolova, A. V. Zhilenko, I. L. Tsarev,, D. A. Napalkov, V. V. Fomin
"... – rivaroxaban and apixaban) were included into the cohort study in parallel groups. In addition to evaluate ..."
 
Vol 14, No 3 (2018) THROMBOSIS OF LEFT ATRIAL APPENDAGE DURING THERAPY WITH DIRECT ORAL ANTICOAGULANT. CLINICAL CASE Abstract  similar documents
I. S. Daaboul, S. Yu. Koroleva, A. A. Kudrjavtseva, A. A. Sokolova, D. A. Napalkov, V. V. Fomin
"... long-term anticoagulant therapy with apixaban in a full dose (5 mg b.i.d.), and the patient ..."
 
Vol 13, No 5 (2017) DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS Abstract  similar documents
S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov
"... рекомендаций Европейской ассоциации сердечного ритма 2015 г. по применению НОАК у пациентов с неклапанной ..."
 
Vol 14, No 2 (2018) NEW DIRECT ORAL ANTICOAGULANTS FOR TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN REAL-WORLD SETTING Abstract  similar documents
Zh. D. Kobalava, S. V. Villevalde, A. A. Shavarov
"... . In comparison of different DOACs against each other apixaban demonstrated lower bleeding risk while patients ..."
 
Vol 12, No 5 (2016) Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease Abstract  similar documents
I. S. Daabul, A. A. Sokolova, D. A. Napalkov
"... предсердий неклапанной этиологии и ХБП. Анализируется возможность максимально безопасного применения ..."
 
Vol 12, No 4 (2016) Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true Abstract  similar documents
Yu. A. Bunin, S. V. Miklishanskaya
"... составляет 1-2%. Неклапанная ФП увеличивает риск развития ишемического инсульта в 5-7 раз. Более 50 ..."
 
Vol 13, No 1 (2017) DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT Abstract  similar documents
D. А. Napalkov, A. A. Sokolova, V. V. Fomin
"... anticoagulants, apixaban is associated with the best adherence to treatment and lowest bleeding incidence ..."
 
Vol 15, No 4 (2019) According to the AUGUSTUS Trial Apixaban (Eliquis ® ) was Found to Be Safer than Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention Abstract  similar documents
Company Pfizer
"... неклапанной фибрилляции предсердий и острым коронарным синдромом и/или чрескожным коронарным вмешательством ..."
 
Vol 12, No 3 (2016) THE PHARMACOKINETICS OF APIXABAN IN PATIENTS WITH CARDIOEMBOLIC STROKE IN ACUTE PHASE Abstract  PDF (Eng)  similar documents
A. V. Kryukov, D. A. Sychev, D. A. Andreev, A. V. Ryabova, N. P. Denisenko, M. A. Loskutnikov, O. I. Vinogradov, M. A. Domashenko
"... Aim. To study pharmacokinetics of apixaban in patients with atrial fibrillation and cardioembolic ..."
 
Vol 11, No 5 (2015) Practical aspects of apixaban use in clinical practice: continuing the theme Abstract  similar documents
S. N. Bel'diev
"... Currently there are no generally accepted guidelines for the use of apixaban together with CYP3A4 ..."
 
Vol 15, No 2 (2019) Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology Abstract  similar documents
S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov, G. Yu. Trufanova
 
Vol 9, No 2 (2013) ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES Abstract  similar documents
Z. M. Safiullina, S. V. Shalaev
"... inhibitors of coagulation factor Xa (rivaroxaban, apixaban), in the treatment of nonvalvular atrial ..."
 
Vol 10, No 3 (2014) EUROPEAN MEDICINES AGENCY APPROVED APIXABAN USE IN CARDIOVERSION Abstract  similar documents
"... European Medicines Agency approved apixaban use in cardioversion. ..."
 
Vol 11, No 2 (2015) PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST Abstract  similar documents
D. A. Sychev, I. I. Sinitsina, G. Yu. Zakharova, M. I. Savel'eva, A. V. Ryabova, A. V. Kryukov, A. Yu. Yurovskii
"... Apixaban is a "new" oral anticoagulant, direct Xa factor inhibitor with a good evidence base ..."
 
Vol 11, No 3 (2015) PHARMACOECONOMIC ASPECTS OF THE PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS AFTER LARGE JOINTS REPLACEMENT Abstract  similar documents
A. V. Rudakova
"... average prices of public bidding for the purchase of drugs (enoxaparin, dabigatran and apixaban) during ..."
 
Vol 13, No 3 (2017) PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION Abstract  similar documents
A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko
"... 1045642 polymorphisms. ABCB1 gene rs4148738 polymorphism was associated with higher apixaban peak ..."
 
Vol 7, No 5 (2011) ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES Abstract  similar documents
Ya. P. Dovgalevskiy, L. E. Kuvshinova, I. V. Graifer, N. V. Furman, P. Ya. Dovgalevskiy
 
Vol 9, No 4 (2013) COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS Abstract  similar documents
V. A. Sulimov, D. A. Napalkov, A. A. Sokolova
"... Indirect comparisons of new oral anticoagulants are performed with focus on their safety. Apixaban ..."
 
Vol 10, No 4 (2014) NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY Abstract  similar documents
D. A. Napalkov, A. A. Sokolova
"... dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile ..."
 
Vol 15, No 5 (2019) Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review Abstract  similar documents
B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov
 
Vol 16, No 1 (2020) Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice Abstract  similar documents
A. A. Zarudsky, A. A. Gavrilova, Т. S. Filinichenko
 
Vol 14, No 3 (2018) APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN Abstract  similar documents
O. D. Ostroumova, A. I. Kochetkov, I. Yu. Orlova, E. A. Smolyarchuk, J. S. Pavlova
"... of efficacy and safety of apixaban in patients with AF, depending on the presence of CHD, PAD, concomitant use ..."
 
Vol 12, No 5 (2016) Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation Abstract  similar documents
N. A. Novikova, A. N. Volovchenko
"... showed the efficacy and safety of rivaroxaban and apixaban in preparation and performance of electrical ..."
 
Vol 14, No 4 (2018) Hepatotoxicity of New Oral Anticoagulants Abstract  similar documents
A. R. Kasimova, A. V. Philippova (Guryanova), A. S. Kolbin
 
Vol 15, No 4 (2019) Optimization of Pharmacotherapy with Direct Oral Anticoagulants: the Need to Choose the Right Dosage Regimen Abstract  similar documents
A. I. Kochetkov, O. D. Ostroumova
"... profile and multimorbidity. In these terms, apixaban stands high among the DOAC class, and its high ..."
 
Vol 12, No 2 (2016) ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION? Abstract  similar documents
D. A. Napalkov, A. A. Sokolova, A. V. Rodionov
"... and safety of apixaban with these of warfarin in patients with atrial fibrillation and a history of ischemic ..."
 
Vol 15, No 6 (2019) Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation Abstract  similar documents
M. A. Gabitova, P. M. Krupenin, A. A. Sokolova, D. A. Napalkov, V. V. Fomin
"... of age with confirmed AF, receiving dabigatran in a reduced dosage, apixaban or rivaroxaban in full ..."
 
Vol 16, No 1 (2020) The Efficacy, Safety and Adherence to Treatment when New Anticoagulants Taking in Over 75 Years Old Patients with Atrial Fibrillation Abstract  similar documents
A. N. Turov, S. V. Panfilov, О. V. Tschiglinzeva
"... , rivaroxaban – in 41.3% (n=178), apixaban – in 20.2% (n=87) of patients. Results. The incidence of new cases ..."
 
Vol 15, No 5 (2019) Findings Released from NAXOS Analysis. Pfizer Company Press Release Abstract  similar documents
article Editorial
"... Компания Pfizer представила результаты когортного исследования NAXOS (EvaluatioN of ApiXaban in ..."
 
Vol 12, No 2 (2016) THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE Abstract  similar documents
S. V. Moiseev
"... New oral anticoagulants that inhibit factor Xa (rivaroxaban, apixaban, edoksaban) or thrombin ..."
 
Vol 7, No 6 (2011) DABIGATRAN ETEXILATE FOR PREVENTION OF CARDIOEMBOLIC COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION: HOW TO DO THE INTERVENTION MORE EFFECTIVE AND SAFER Abstract  similar documents
I. S. Yavelov
"... неклапанной фибрилляции предсердий. С учетом результатов крупного рандомизированного клинического исследования ..."
 
Vol 11, No 5 (2015) Cost-effectiveness of new oral anticoagulants in the treatment and secondary prevention of venous thromboembolism Abstract  similar documents
A. V. Rudakova
"... Aim. To assess the cost-effectiveness of apixaban in the treatment and secondary prevention ..."
 
Vol 9, No 4 (2013) COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE Abstract  similar documents
L. E. Kuvshinova, N. V. Furman, P. V. Dolotovskaya, Ya. P. Dovgalevsky
"... -valvular atrial fibrillation (NVAF) during preparation for elective cardioversion. Material and methods ..."
 
Vol 8, No 1 (2012) PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
Yu. B. Belousov, V. Yu. Mareev, I. S. Yavelov, D. Yu. Belousov
"... фармакоэкономическую эффективность применения дабигатрана этексилата в сравнении с варфарином в профилактике сердечно ..."
 
Vol 13, No 5 (2017) WARFARIN AND ITS IMPORTANCE IN THE ERA OF NEW ORAL ANTICOAGULANTS. ISSUES OF MONITORING THE EFFECTIVENESS AND SAFETY OF TREATMENT Abstract  similar documents
S. Yu. Martsevich, Y. V. Lukina
"...   of new OAC (NOAC) also appeared. In Russia, dabigatran, rivaroxaban and apixaban have been registered ..."
 
Vol 8, No 2 (2012) COMPARISON OF PHARMACOKINETICS AND PHARMACODYNAMICS OF THE ORIGINAL AND GENERIC ENALAPRIL IN THE ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION Abstract  similar documents
O. P. Bobrova, M. M. Petrova
"... Цель. Изучить фармакокинетические, фармакодинамические и фармакоэкономические показатели ..."
 
Vol 4, No 4 (2008) ECONOMIC REASONS FOR GENERIC CHOICE Abstract  similar documents
N. P. Kutishenko, S. Y. Martsevich, S. N. Tolpygina, J. V. Lukina
"... дженериков и оригинального препарата проведена фармакоэкономическая оценка изучаемых препаратов. ..."
 
Vol 15, No 6 (2019) Adherence to Treatment with New Oral Anticoagulants in Atrial Fibrillation Patients in Real Clinical Practice (Results of the ANTEY Study) Abstract  similar documents
S. Yu. Martsevich, Yu. V. Lukina, N. P. Kutishenko, S. N. Tolpygina, V. P. Voronina, N. A. Dmitrieva, O. V. Lerman, N. A. Komkova
"... recommended the use of rivaroxaban; 47 (23.4%) – the use of dabigatran and 43 (21.4%) – the use of apixaban ..."
 
Vol 6, No 4 (2010) PHARMACOECONOMIC ANALYSIS OF CARVEDILOL THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC RISK FACTORS (ACCORDING TO THE CAMELLIA STUDY) Abstract  similar documents
S. Y. Martsevich, N. P. Kutishenko, A. D. Deev, S. A. Shalnova, R. G. Oganov
"... Цель. Провести фармакоэкономический анализ «затраты-эффективность» терапии артериальной гипертонии ..."
 
Vol 6, No 6 (2010) EFFICACY AND SAFETY OF SINUS RHYTHM RESTORATION WITH AMIODARONE AND PROPAFENONE IN OUTPATIENTS, ECONOMIC ASPECTS (BASED ON DATA OF N.A. SEMASHKO NORTHERN MEDICAL CLINICAL CENTER) Abstract  similar documents
T. A. Istomina, E. V. Serdechnaya, L. A. Kulminskaya, B. A. Tatarskiy, E. V. Kazakevich, V. L. Lipskiy, S. I. Martyushov
 
Vol 10, No 4 (2014) PHARMACOECONOMIC ANALYSIS OF ANTIHYPERTENSIVE DRUG COMBINATIONS USE Abstract  similar documents
E. I. Tarlovskaya, Y. A. Balandina, N. S. Maximchuk-Kolobova
"... Цель. Фармакоэкономический анализ двух комбинаций препаратов, в состав которых входят ингибитор ..."
 
Vol 7, No 1 (2011) THE CHOICE OF THE DRUG AMLODIPINE FOR THE HYPERTENSION TREATMENT FROM THE STANDPOINT OF ECONOMIC FEASIBILITY Abstract  similar documents
S. Yu. Martsevich, N. A. Dmitrieva, A. D. Deev, Yu. V. Lukina, L. A. Sokolova, V. V. Yakusevich
 
Vol 8, No 1 (2012) CHANGES IN THE COSTS OF HYPERTENSIVE CRISIS THERAPY DUE TO OPTIMIZATION OF DRUG SUPPLY IN THE PRE-ADMISSION CARE Abstract  similar documents
N. I. Gaponova, N. F. Plavunov, V. L. Baratashvili
 
Vol 9, No 1 (2013) PHARMACOEPIDEMIOLOGICAL AND PHARMACOECONOMIC STUDIES OF ANTIHYPERTENSIVE TREATMENT IN RUSSIA. Analytical Review Abstract  similar documents
T. S. Romanenko, A. V. Kontsevaya, S. V. Fitilev
"... Представлен обзор фармакоэпидемиологических и фармакоэкономических исследований антигипертензивной ..."
 
Vol 6, No 4 (2010) ANTITHROMBOTIC THERAPY IN NONVALVULAR ATRIAL FIBRILLATION: PROBLEMS AND PROSPECTS Abstract  similar documents
A. Y. Rychkov, N. Y. Khor'kova, A. A. Bliznyakov
"... осложнений, ассоциированных с неклапанной фибрилляцией предсердий, в частности ишемического инсульта. В ..."
 
Vol 10, No 2 (2014) SECONDARY PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: THE CLINICIANS’ VIEWPOINT Abstract  similar documents
E. A. Drozdova
"... . Рассматриваются актуальные проблемы ведения больных с инсультами, возникшими на фоне неклапанной фибрилляции ..."
 
Vol 10, No 4 (2014) MODERN APPROACHES TO ANTICOAGULANT THERAPY DURING CATHETER ABLATION TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
E. A. Belikov, K. V. Davtyan, O. N. Tkacheva
 
Vol 16, No 1 (2020) Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients Abstract  similar documents
A. B. Sumarokov, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin
"... therapy turned out to be the most promising for clinical use, since studies with dabigatran and apixaban ..."
 
Vol 7, No 5 (2011) ECONOMIC BENEFITS OF LEFT VENTRICULAR HYPERTROPHY REGRESSION IN PATIENTS WITH ARTERIAL HYPERTENSION Abstract  similar documents
E. I. Tarlovskaya, N. S. Maksimchuk, S. V. Malchicova, M. V. Avksentieva, I. E. Sapozhnikova, Y. A. Balandina
"... фиксированной комбинации амлодипин/валсартан имеет не только клинические, но и фармакоэкономические преимущества ..."
 
Vol 9, No 3 (2013) ECONOMIC EVALUATION OF COMBINED THERAPY OF ARTERIAL HYPERTENSION BY MARKOV’S MODELING Abstract  similar documents
N. S. Maksimchuk-Kolobova, E. I. Tarlovskaya, S. V. Malchikova
 
Vol 10, No 4 (2014) RATIONAL PHARMACOTHERAPY BASED ON PHARMACOECONOMIC DATA AUDIT: PRINCIPLES AND APPLICATION IN BULGARIA Abstract  similar documents
T. Vekov
"... Рассмотрены теоретические основы использования фармакоэкономического анализа для оценки ..."
 
Vol 8, No 3 (2012) PHARMACOECONOMIC ASPECTS OF NICOTINE ADDICTION TREATMENT IN PATIENTS WITH ANGINA REQUIRING CARDIAC SURGERY Abstract  similar documents
A. V. Rudakova, M. S. Berezhnova
"... . Заключение. Терапия варениклином пациентов со стенокардией является фармакоэкономически высокоэффективной как ..."
 
Vol 8, No 2 (2012) PRELIMINARY RESULTS OF COMPARATIVE PHARMACOECONOMIC PROSPECTIVE STUDY OF DIFFERENT THERAPIES OF ARTERIAL HYPERTENSION Abstract  similar documents
E. I. Tarlovskaya, N. S. Maksimchuk, S. V. Malchikova, M. V. Avksentieva
"... Цель. Провести сравнительный фармакоэкономический анализ двух различных вариантов ..."
 
Vol 14, No 2 (2018) PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONS Abstract  similar documents
S. K. Zyryanov, A. E. Cheberda, D. Yu. Belousov
"... благоприятного влияния на течение коморбидного сахарного диабета (СД). Однако вопрос о фармакоэкономических ..."
 
Vol 12, No 1 (2016) Pharmacoeconomic analysis of heart rate slowing drugs in patients with ischemic heart disease Abstract  similar documents
E. I. Tarlovskaya, T. I. Chudinovskikh
"... бисопролола. Фармакоэкономический анализ выявил, что для урежения ЧСС более выгодным с экономической точки ..."
 
Vol 8, No 6 (2012) HOW TO USE DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
S. V. Moiseev
"... у 18000 пациентов с неклапанной фибрилляцией предсердий (ФП) дабигатран в дозе 150 мг два раза в ..."
 
Vol 12, No 5 (2016) The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin Abstract  similar documents
I. Yu. Koroleva, I. V. Kolesnichenko, V. P. Nosov, M. V. Zlobin, D. I. Abelevich
"... системных тромбоэмболических осложнений (ТЭО), кровотечений у пациентов с неклапанной фибрилляцией ..."
 
Vol 6, No 1 (2010) SOME ASPECTS OF THE LISINOPRIL USAGE IN ARTERIAL HYPERTENSION TREATMENT Abstract  similar documents
N. A. Jaiani
"... , рассматриваются фармакоэкономические аспекты применения лизиноприла при артериальной гипертонии. ..."
 
Vol 12, No 4 (2016) New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer) Abstract  similar documents
Article Editorial
"... пациентов с фибрилляцией предсердий неклапанного генеза. Эти результаты дополняют и вновь подтверждают ..."
 
Vol 15, No 1 (2019) Comparative Analysis of Antithrombotic Therapy in In-Patients with Atrial Fibrillation Abstract  similar documents
V. I. Petrov, O. V. Shatalova, A. S. Gerasimenko, V. S. Gorbatenko
"... предсердий (ФП) неклапанной этиологии, госпитализированных в кардиологическое отделение многопрофильного ..."
 
Vol 12, No 4 (2016) Application of rivaroxaban in clinical practice: results of a prospective observational study XANTUS in patients with atrial fibrillation Abstract  similar documents
S. G. Kanorskii
"... обычной клинической практике у пациентов с неклапанной фибрилляцией предсердий. У последовательных ..."
 
Vol 14, No 4 (2018) Possibilities of Using Rivaroxaban in Elderly Patients with Atrial Fibrillation: Data from Randomized Studies and Real Clinical Practice Abstract  similar documents
N. M. Vorobyeva, O. N. kacheva
"... неклапанной фибрилляцией предсердий. Приводятся результаты рандомизированного исследования ROCKET-AF, включая ..."
 
Vol 11, No 2 (2015) ANTICOAGULANT THERAPY IN EVERYDAY CLINICAL PRACTICE: DATA OF THE RETROSPECTIVE CROSS-SECTIONAL STUDY Abstract  PDF (Eng)  similar documents
V. A. Sulimov, D. A. Napalkov, A. A. Sokolova, A. V. Jilenko, O. S. Anikina
"... неклапанной этиологии в рутинной клинической практике получают неадекватную антитромботическую терапию ..."
 
Vol 4, No 3 (2008) COMPARATIVE EFFICACY OF ACE INHIBITORS (RAMIPRIL VS ENALAPRIL) IN TREATMENT OF CHRONIC HEART FAILURE IN WOMEN Abstract  similar documents
S. N. Tereshchenko, I. V. Zhirov, E. V. Malichenko, E. E. Kazantseva
"... неклапанной этиологии. Пациентки рандомизированы в группы приема рамиприла и эналаприла в дополнение к ..."
 
Vol 12, No 3 (2016) THE PREDICTION OF ATRIAL FIBRILLATION RECURRENCE AT VARIOUS METHODS OF SINUS RHYTHM RECOVERY Abstract  PDF (Eng)  similar documents
T. Y. Gromyko, S. A. Sayganov
"... восстановления синусового ритма.  Материал и методы. Обследовано 153 пациента с неклапанной формой ФП ..."
 
Vol 5, No 5 (2009) THE COMPARATIVE COST-EFFICACY ANALYSIS OF VARIOUS ANTIHYPERTENSIVE THERAPIES Abstract  similar documents
S. V. Malchikova, E. I. Tarlovskaya
"... С - амлодипин и лизиноприл; группа D -амлодипин и бисопролол. Для фармакоэкономического анализа ..."
 
Vol 15, No 2 (2019) Cardiovascular medicine prices as an indicator of access to medicines and their rational use Abstract  similar documents
C M. Razzakova, L. E. Ziganshina
"... фармакоэкономическую оценку прямых затрат пациентов на лекарства для лечения артериальной гипертензии в 2015 г Для ..."
 
Vol 7, No 5 (2011) COMPARATIVE EFFICACY AND SAFETY OF HYPOLIPIDEMIC THERAPY WITH GENERIC AND ORIGINAL MEDICINAL PRODUCTS OF SIMVASTATIN Abstract  similar documents
E. I. Tarlovskaya, Yu. A. Balandina, I. E. Sapozhnikova, N. S. Maksimchuk
"... Цель. Сравнить эффективность, безопасность и фармакоэкономические характеристики оригинального и ..."
 
Vol 7, No 6 (2011) COMPARATIVE EFFICACY OF COMBINED ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH MODERATE ARTERIAL HYPERTENSION ACCOMPANIED BY TYPE 2 DIABETES Abstract  similar documents
E. I. Tarlovskaya, Yu. A. Balandina, I. E. Sapozhnikova, N. S. Maksimchuk
"... (с 40% до 23%) и С (с 40% до 25%). При фармакоэкономическом анализе выявлено, что комбинация С ..."
 
Vol 3, No 5 (2007) CLINICAL AND PHARMACOKINETIC EQUIVALENCE OF ORIGINAL AND GENERIC AMLODIPINE IN PATIENTS WITH MILD-TO-MODERATE ARTERIAL HYPERTENSION Abstract  similar documents
N. A. Belolipetskiy, S. N. Tolpygina, J. B. Zverkov, V. V. Pisarev, I. E. Koltunov, V. G. Belolipetskaya, S. J. Martsevich
"... плазме крови и фармакоэкономическую целесообразность их применения у больных мягкой и умеренной ..."
 
Vol 4, No 4 (2008) COMPARISON OF DIFFERENT STRATEGIES OF ANTIHYPERTENSIVE THERAPY IN OUT-PATIENT CLINIC Abstract  similar documents
O. A. Plejko, A. O. Konradi
"... для достижения целевого АД. Проведен фармакоэкономический анализ терапии АГ в каждой группе ..."
 
Vol 8, No 1 (2012) ANALYSIS OF COST STRUCTURE FOR PHARMACOTHERAPY OF PATIENTS WITH STABLE ANGINA (THE CASE OF CARDIOLOGY DEPARTMENT OF TVER REGIONAL CLINICAL HOSPITAL) Abstract  similar documents
M. A. Demidova, N. N. Kirilenko
"... анализе затрат частично использовались фармакоэкономические методы анализа, в частности ABC анализ ..."
 
Vol 8, No 5 (2012) RISK OF THROMBOEMBOLIC COMPLICATIONS AND ANTITHROMBOTIC THERAPY IN IN-PATIENTS WITH PERMANENT AND RECURRENT ATRIAL FIBRILLATION IN REAL CLINICAL PRACTICE Abstract  similar documents
I. V. Grajfer, L. E. Kuvshinova, P. V. Dolotovskaya, O. V. Reshet'ko, N. V. Furman
"... много- профильных стационаров на протяжении года по поводу неклапанной ФП. Оценивали риск ..."
 
Vol 15, No 5 (2019) Left Atrial Phasic Function in Patients with Hypertension and Recurrent Atrial Fibrillation: Gender Differences of the Relationship with Diastolic Dysfunction and Central Aortic Pressure Abstract  similar documents
E. V. Kokhan, E. M. Ozova, V. A. Romanova, G. K. Kiyakbaev, Zh. D. Kobalava
"... пациентов – 30 мужчин и 37 женщин с неклапанной рецидивирующей ФП, АГ и гипертрофией ЛЖ. При эхокардиографии ..."
 
Vol 4, No 3 (2008) ESTIMATION OF CLINICAL AND PHARMACOKINETIC EQUIVALENCE OF ORIGINAL AND GENERIC CARVEDILOLS IN PATIENTS WITH HYPERTENSION OF 1-2 GRADES Abstract  similar documents
E. I. Bambysheva, S. N. Tolpygina, D. F. Guranda, I. E. Koltunov, V. G. Belolipetskaja, S. J. Martsevich
"... под контролем концентрации в плазме, а также фармакоэкономическую целесообразность их применения у ..."
 
1 - 81 of 81 Items

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)